Testosterone Accessibility & Clinical Safety: What Physicians Need to Know

The Policy Shift: Context & Concerns

Recent regulatory proposals to streamline testosterone prescribing authority represent a significant departure from the current prescribing paradigm. While expanded access addresses real gaps in care for hypogonadal men, the underlying clinical question remains unchanged: How do we maximize therapeutic benefit while minimizing iatrogenic harm?

The honest answer is that testosterone is not benign. It's a potent androgenic steroid that upregulates the prostate, increases hematocrit, shifts lipid metabolism, and modulates cardiovascular hemodynamics. Easier prescribing without corresponding improvements in baseline screening and monitoring protocols is a recipe for preventable morbidity.

Why Baseline Labs Are Non-Negotiable

Before any testosterone initiation—whether prescribed by a cardiologist, primary care physician, or urologist—baseline labs must include:

Essential Baseline Panel

Total testosterone & free testosterone (LC-MS/MS method, not immunoassay)
LH & FSH — critical for distinguishing primary vs. secondary hypogonadism
Estradiol (sensitive assay, <10 pg/mL lower detection limit)
PSA & digital rectal exam — mandatory before age-based screening guidelines
CBC with differential — baseline hematocrit critical
Lipid panel (fasting) — testosterone increases VLDL and triglycerides
Liver function tests (AST, ALT, GGT) — testosterone is 17-alkylated in some formulations
Prostate ultrasound — if PSA >4 ng/mL or abnormal DRE
Cardiovascular risk assessment — EKG, consider stress testing in men >55 or with risk factors

Why These Matter

LH/FSH differentiation is critical. A man with low testosterone and low LH/FSH has secondary hypogonadism (pituitary/hypothalamic dysfunction). His testicular axis is intact but suppressed. Exogenous testosterone will further suppress LH/FSH, potentially causing testicular atrophy and permanent azoospermia if fertility is desired.

Conversely, primary hypogonadism (high LH/FSH, low testosterone) indicates testicular failure. Testosterone replacement is appropriate, but fertility options are limited.

Estradiol baseline matters because testosterone aromatizes to estradiol. Men starting testosterone will see estradiol rise. Elevated estradiol (>50 pg/mL) increases gynecomastia risk, fluid retention, and potentially thromboembolic risk.

Therapeutic Targets & Optimal Ranges

Reference ranges and therapeutic targets are not synonymous. The clinical laboratory reference range for total testosterone is typically 300–1000 ng/dL—a range designed to capture 95% of healthy men. But therapeutic efficacy and safety operate in a narrower band.

Evidence-Based Therapeutic Targets

Total testosterone: 500–700 ng/dL
Free testosterone: 100–200 pg/mL (approximately 2–4% of total)
Estradiol: 20–40 pg/mL (some evidence suggests <30 pg/mL reduces cardiovascular risk)
Hematocrit: Stay <54% (phlebotomy if higher)
PSA: Stable or declining (not rising >0.75 ng/mL/year)

Clinically, we're targeting physiologic replacement—restoring testosterone to youthful levels without supraphysiologic dosing. Doses should be titrated to achieve these targets, not maxed based on convenience.

The Synergy Question: Peptides vs. Testosterone Replacement

A frequently overlooked clinical consideration: GnRH agonists and GHRH secretagogues (sermorelin, ipamorelin) may offer an alternative pathway to testosterone replacement, particularly in secondary hypogonadism.

These peptides stimulate endogenous GnRH pulsatility and GH secretion, which can:

Restore endogenous LH/FSH (preserving fertility)
Maintain testicular size and spermatogenesis
Provide body composition benefits similar to testosterone
Avoid suppression of the HPG axis

For men with secondary hypogonadism who want to preserve fertility, peptide strategies may be underutilized relative to exogenous testosterone. Policy changes should address this gap.

Monitoring Protocol During Treatment

Easier prescribing must pair with mandatory monitoring schedules:

Weeks 4–6: Total/free testosterone, estradiol, hematocrit
Week 12: Repeat labs + lipid panel
Every 6 months thereafter: Total/free testosterone, estradiol, CBC, PSA
Annually: Full metabolic panel, lipid panel, cardiovascular assessment

If PSA rises >0.75 ng/mL/year or absolute PSA >4 ng/mL, urology referral is mandatory—not optional.

The Bottom Line

Expanded access to testosterone prescribing can serve real patient populations. But policy reform without corresponding clinical infrastructure improvements—particularly baseline screening and ongoing monitoring—represents regulatory capture by convenience, not evidence.

Physicians adopting easier prescribing pathways have an ethical obligation to implement rigorous baseline and periodic laboratory protocols. Testosterone is not innocuous. It works. But it works within a defined window, and that window requires vigilance.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.